CLEAN BRIEFING DOCS
Sneeze breeze? No FDA ragweed quibbles for Merck, Alk-Abello
By Randy Osborne
Friday, January 24, 2014
Briefing papers for the meeting next week of the FDA’s Allergenic Products Advisory Committee suggest that the panel will green-light the sublingual ragweed allergy therapy from Alk-Abello A/S and Merck and Co. Inc., just as the grass-pollen allergy tablet sailed through last month.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.